Scientists unravel the structure of common bacterial wall-building protein, setting stage for new antibacterial therapies
The wall that surrounds bacteria to shield them from external assaults has long been a tantalizing target for drug therapies. Indeed, some of modern medicine’s most reliable antibiotics disarm harmful bacteria by disrupting the proteins that build their protective armor.
<iframe src=”https://player.vimeo.com/video/262243190″ width=”640″ height=”360″ frameborder=”0″ webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>
For decades, scientists knew of only one wall-making protein family. Then, in 2016, a team of Harvard Medical School scientists discovered that a previously unsuspected family of proteins that regulate cell division and cell shape had a secret skill: building bacterial walls.
Now, in another scientific first described March 28 in Nature, members of the same research team have revealed the molecular building blocks—and a structural weak spot—of a key member of that family.
“Our latest findings reveal the molecular structure of RodA and identify targetable spots where new antibacterial drugs could bind and subvert its work,” said study senior investigator Andrew Kruse, associate professor of biological chemistry and molecular pharmacology at Harvard Medical School.
The newly profiled protein, RodA, belongs to a family collectively known as SEDS proteins, present in nearly all bacteria. SEDS” near-ubiquity renders these proteins ideal targets for the development of broad-spectrum antibiotics to disrupt their structure and function, effectively neutralizing a range of harmful bacteria.
A weak link
In their earlier work, the scientists showed that RodA builds the cellular wall by knitting together large sugar molecules with clusters of amino acids. Once constructed, the wall encircles the bacterium, keeping it structurally intact, while repelling toxins, drugs and viruses.
The latest findings, however, go a step further and pinpoint a potential weak link in the protein’s makeup.
Specifically, the protein’s molecular profile reveals structural features reminiscent of other proteins whose architecture Kruse has disassembled. Among them, the cell receptors for the neurotransmitters acetylcholine and adrenaline, which are successfully targeted by medications that boost or stem the levels of these nerve-signaling chemicals to treat a range of conditions, including cardiac and respiratory diseases.
One particular feature caught the scientists’ attention—a pocket-like cavity facing the outer surface of the protein. The size and shape of the cavity, along with the fact that it is accessible from the outside, make it a particularly appealing drug target, the researchers said.
“What makes us excited is that this protein has a fairly discrete pocket that looks like it could be easily and effectively targeted with a drug that binds to it and interferes with the protein’s ability to do its job,” said study co-senior author David Rudner, professor of microbiology and immunobiology at Harvard Medical School.
In a set of experiments, researchers altered the structure of RodA in two bacterial species—the textbook representatives of the two broad classes that make up most of disease-causing bacteria. One of them was Escherichia coli, which belongs to a class of organisms with a double-cell membrane known as gram-negative bacteria, so named due to a reaction to staining test used in microbiology. The other bacterium was Bacillus subtilis, a single-membrane organism that belongs to so-called gram-positive bacteria.
When researchers induced even mild alterations to the structure of RodA’s cavity, the protein lost its ability to perform its work. E. coli and B. subtilis cells with disrupted RodA structure rapidly enlarged and became misshapen, eventually bursting and leaking their contents.
“A chemical compound—an inhibitor—that binds to this pocket would interfere with the protein’s ability to synthesize and maintain the bacterial wall,” Rudner said. “That would, in essence, crack the wall, weaken the cell and set off a cascade that eventually causes it to die.”
Additionally, because the protein is highly conserved across all bacterial species, the discovery of an inhibiting compound means that, at least in theory, a drug could work against many kinds of harmful bacteria.
“This highlights the beauty of super-basic scientific discovery,” said co-investigator Thomas Bernhardt, professor of microbiology and immunobiology at Harvard Medical School. “You get to the most fundamental level of things that are found across all species, and when something works in one of them, chances are it will work across the board.”
Solving for X
To determine RodA’s structure, scientists used a visualization technique known as X-ray crystallography, which reveals the molecular architecture of protein crystals based on a pattern of scattered X-ray beams. The technique requires two variables—the intensity of scattered X-rays and a so-called “phase angle,” a property related to the configuration of the atoms in a protein. The latter is measured indirectly, typically by using a closely related protein as a substitute to calculate the variable.
In this case, however, the team had on its hands a never-before-described protein with no known molecular siblings.
“In most cases you can use a related structure and bootstrap to a solution,” Kruse said. “In this case, we couldn’t do that. We had to predict what RodA looked like without any prior information about it.”
They needed a new way to solve for X.
In a creative twist, researchers turned to evolution and predictive analytics. Working with Debora Marks, assistant professor of systems biology at Harvard Medical School, they constructed a virtual model of the RodA’s folding pattern by analyzing the sequences of its closest evolutionary cousins.
The success of this “roundabout” approach, researchers said, circumvents a significant hurdle in field of structural biology and can open the doors toward defining the structures of many more newly discovered proteins.
“These insights underscore the importance of creative crosspollination among scientists from multiple disciplines and departments,” said study first author Megan Sjodt, a research fellow in biological chemistry and molecular pharmacology at Harvard Medical School. “We believe our results set the stage for subsequent work toward the discovery and optimization of new classes of antibiotics.”
Learn more: A Chink in Bacteria’s Armor
The Latest on: Antibiotics
via Google News
The Latest on: Antibiotics
New Research Points To The Future Of Antibiotics
on April 17, 2018 at 1:08 am
Newly discovered antibiotics could be crucial in fighting drug-resistant bacteria. Researchers from the University of Illinois at Chicago and Nosopharm, a biotechnology company based in Lyon, France discovered the new class of antibiotics, as told in an ... […]
Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
on April 16, 2018 at 12:39 pm
Use of antibiotics may be associated with reduced effectiveness of immune checkpoint inhibitors (ICIs) for patients with advanced renal cell carcinoma (RCC) and non-small-cell lung cancer (NSCLC), according to the results of a study published in Annals of ... […]
New class of antibiotics to combat drug resistance
on April 15, 2018 at 12:08 pm
Chicago - A new class of antibiotic has been discovered. The chemical kills bacteria by binding to ribosome. This disrupts protein synthesis, and stops the microbial cell from replicating. This is a step forward in the search for new antimicrobials. […]
Treated Farm Waste Contains Traces Of Antibiotics, Possibly Contributing To Spread Of Resistance
on April 13, 2018 at 3:30 pm
After analyzing two of the “most elite” waste treatment systems on farms today, two studies from the University at Buffalo found that antibiotics aren’t fully removed from the manure. Instead, the waste still contains antibiotics that may be ... […]
Remnants Of Antibiotics Persist In Treated Farm Waste
on April 12, 2018 at 7:20 pm
Each year, farmers in the U.S. purchase tens of millions of pounds of antibiotics that are approved for use in cows, pigs, fowl and other livestock. When farmers repurpose the animals’ manure as fertilizer or bedding, traces of the medicines leach into ... […]
Want To Avoid Unnecessary Antibiotics? Be Careful What Time Of Day You See Your Doctor
on April 10, 2018 at 7:45 am
Too often, people with viral illness leave the doctor’s office with prescriptions for antibiotics. That’s a real problem. Antibiotics don’t treat viruses, often cause side effects, and when taken too often, lead to drug resistance. So when you have a ... […]
Antibiotics do work on viruses
on April 9, 2018 at 9:04 am
Everybody knows antibiotics don’t work on viruses, right? Not, it turns out, if you’re a female mouse with a nasty case of genital herpes, in which case a well-timed dose of antibiotic might be just the thing, according to new research published in the ... […]
Novel Antibiotics Could Arise from Adhesion Protein Structure Analysis
on April 9, 2018 at 6:55 am
Scientists at Harvard Medical School, the University of California–San Francisco, and the University of Georgia have described how the protein that allows strep and staph bacteria to stick to human cells is prepared and packaged. Their study ... […]
Research team identifies new class of antibiotics to fight drug resistance
on April 7, 2018 at 4:36 am
Researchers from the University of Illinois at Chicago and Nosopharm, a biotechnology company based in Lyon, France, are part of an international team reporting on the discovery of a new class of antibiotics. The antibiotic, first identified by Nosopharm ... […]
via Bing News